11:09 AM EDT, 09/16/2025 (MT Newswires) -- Biofrontera (BFRI) said Tuesday that the last person has completed the active treatment stage of a phase 3 trial assessing Ameluz photodynamic therapy to potentially treat mild to moderate actinic keratoses on the extremities, neck and trunk.

All of the 172 people enrolled are now in a 12-month follow-up phase, which is expected to be completed in Q2 2026, the company said, adding that pending positive results, it will file a supplemental new drug application with the US Food and Drug Administration that quarter.

Actinic keratosis is a precancerous skin disease found on sun-exposed areas of the body, Biofrontera said.

The company's shares were up 1.8% in recent trading.

Price: 0.85, Change: +0.02, Percent Change: +1.79